Aethlon Medical Reports Cash Balance of Approximately $7M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy AEMD?
As of December 31, 2025, Aethlon had a cash balance of approximately $7M. "We remain committed to advancing our clinical programs and research initiatives with operational discipline," said James Frakes, CEO and CFO of Aethlon Medical. "Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AEMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AEMD
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present at the Life Sciences Investor Forum on March 12, 2026, providing real-time interaction opportunities with investors, thereby enhancing the company's visibility and credibility among stakeholders.
- Clinical Trial Progress: The active progression of Cohort 2 in the Australian oncology trial reflects the company's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's future potential.
- Scientific Research Advancement: Continued advancements in the company's extracellular vesicle research platform, including Long COVID data submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, opening new market opportunities for the company.
- Technology Development: Ongoing evaluation of Hemopurifier® compatibility with a simplified blood treatment system is expected to support broader clinical applications, further enhancing the company's competitiveness in the medical device market.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present live at the Life Sciences Investor Forum on March 12, 2026, hosted by VirtualInvestorConferences.com, which is expected to attract significant attention from investors and industry professionals, thereby enhancing the company's visibility among investors.
- Clinical Progress Update: The active progression of Cohort 2 in the Australian oncology trial reflects Aethlon's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's research and development capabilities.
- Scientific Research Advancement: Continued advancements in Aethlon's preclinical extracellular vesicle research platform, particularly with Long COVID data published on bioRxiv and submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, potentially attracting more investor interest in its R&D direction.
- Ongoing Technology Development: The evaluation of Hemopurifier® compatibility with a simplified blood treatment system is ongoing, aimed at supporting broader clinical applications, which not only enhances the product's market competitiveness but may also open new revenue growth opportunities for the company.
See More
Aethlon Medical to Present at Emerging Growth Conference
- Conference Participation: Aethlon Medical is set to present at the Emerging Growth Conference on February 25, 2026, from 12:30 to 1:00 PM ET, allowing direct interaction between the CEO, CFO, and investors, thereby enhancing engagement with the investment community.
- Investor Interaction Format: The event will be conducted via video webcast, enabling investors to submit questions in advance, which will foster confidence and participation in the company's growth narrative.
- Hemopurifier® Device Overview: Aethlon's Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation, showcasing significant therapeutic potential, particularly in oncology and infectious diseases.
- Future Development Outlook: Aethlon Medical aims to address unmet needs in oncology and infectious diseases, with the Hemopurifier receiving U.S. FDA Breakthrough Device Designation, highlighting its clinical relevance and market potential.
See More
Aethlon Medical Reports Q3 2026 Earnings and Trial Progress
- Clinical Trial Progress: Aethlon Medical has completed two Hemopurifier treatments in its Australian oncology trial's second cohort, with a third patient scheduled for treatment by the end of February, demonstrating the company's ongoing commitment to clinical advancement that may pave the way for future therapeutic options.
- Financial Update: As of December 31, 2025, the company reported a cash balance of approximately $7 million, and while the operating loss for the quarter increased to $2.06 million, operating expenses for the nine-month period decreased by 27% compared to last year, reflecting effective cost control measures.
- Recruitment Strategy Optimization: Management highlighted an increase in potential trial participants due to new recruitment strategies, which is expected to accelerate the advancement to Cohort 3, thereby enhancing the Hemopurifier's application potential in oncology and infusion centers.
- Future Outlook: The management plans to conduct a Data Safety Monitoring Board review in late March to determine whether to advance to Cohort 3, indicating the company's confidence in its clinical trials and a positive outlook for future growth.
See More
Aethlon Medical Reports Q3 Loss, Cash Reserves Decline
- Earnings Miss: Aethlon Medical reported a Q3 GAAP EPS of -$2.45, missing estimates by $0.03, indicating ongoing challenges in profitability that could undermine investor confidence.
- Cash Reserves Pressure: As of December 31, 2025, Aethlon's cash balance stood at approximately $7.0 million, reflecting liquidity pressures that may limit future R&D and operational activities.
- Rising Operating Expenses: Consolidated operating expenses for Q3 2025 were approximately $2.06 million, up $250,000 or 13.6% from $1.81 million in the same period of 2024, suggesting challenges in cost control that could impact overall financial health.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance on Aethlon's future prospects, particularly as the company requires additional funding to support its R&D projects, potentially leading to stock price volatility.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present at the Life Sciences Investor Forum on March 12, 2026, providing real-time interaction opportunities with investors, thereby enhancing the company's visibility and credibility among stakeholders.
- Clinical Trial Progress: The active progression of Cohort 2 in the Australian oncology trial reflects the company's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's future potential.
- Scientific Research Advancement: Continued advancements in the company's extracellular vesicle research platform, including Long COVID data submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, opening new market opportunities for the company.
- Technology Development: Ongoing evaluation of Hemopurifier® compatibility with a simplified blood treatment system is expected to support broader clinical applications, further enhancing the company's competitiveness in the medical device market.
See More
Aethlon Medical to Present at Life Sciences Investor Forum
- Investor Forum Participation: Aethlon Medical's CEO and CFO, Jim Frakes, will present live at the Life Sciences Investor Forum on March 12, 2026, hosted by VirtualInvestorConferences.com, which is expected to attract significant attention from investors and industry professionals, thereby enhancing the company's visibility among investors.
- Clinical Progress Update: The active progression of Cohort 2 in the Australian oncology trial reflects Aethlon's ongoing commitment to clinical execution, which is likely to bolster investor confidence in the company's research and development capabilities.
- Scientific Research Advancement: Continued advancements in Aethlon's preclinical extracellular vesicle research platform, particularly with Long COVID data published on bioRxiv and submitted for peer review, support the Hemopurifier's potential as a multi-indication therapeutic approach, potentially attracting more investor interest in its R&D direction.
- Ongoing Technology Development: The evaluation of Hemopurifier® compatibility with a simplified blood treatment system is ongoing, aimed at supporting broader clinical applications, which not only enhances the product's market competitiveness but may also open new revenue growth opportunities for the company.
See More
Aethlon Medical to Present at Emerging Growth Conference
- Conference Participation: Aethlon Medical is set to present at the Emerging Growth Conference on February 25, 2026, from 12:30 to 1:00 PM ET, allowing direct interaction between the CEO, CFO, and investors, thereby enhancing engagement with the investment community.
- Investor Interaction Format: The event will be conducted via video webcast, enabling investors to submit questions in advance, which will foster confidence and participation in the company's growth narrative.
- Hemopurifier® Device Overview: Aethlon's Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation, showcasing significant therapeutic potential, particularly in oncology and infectious diseases.
- Future Development Outlook: Aethlon Medical aims to address unmet needs in oncology and infectious diseases, with the Hemopurifier receiving U.S. FDA Breakthrough Device Designation, highlighting its clinical relevance and market potential.
See More
Aethlon Medical Reports Q3 2026 Earnings and Trial Progress
- Clinical Trial Progress: Aethlon Medical has completed two Hemopurifier treatments in its Australian oncology trial's second cohort, with a third patient scheduled for treatment by the end of February, demonstrating the company's ongoing commitment to clinical advancement that may pave the way for future therapeutic options.
- Financial Update: As of December 31, 2025, the company reported a cash balance of approximately $7 million, and while the operating loss for the quarter increased to $2.06 million, operating expenses for the nine-month period decreased by 27% compared to last year, reflecting effective cost control measures.
- Recruitment Strategy Optimization: Management highlighted an increase in potential trial participants due to new recruitment strategies, which is expected to accelerate the advancement to Cohort 3, thereby enhancing the Hemopurifier's application potential in oncology and infusion centers.
- Future Outlook: The management plans to conduct a Data Safety Monitoring Board review in late March to determine whether to advance to Cohort 3, indicating the company's confidence in its clinical trials and a positive outlook for future growth.
See More
Aethlon Medical Reports Q3 Loss, Cash Reserves Decline
- Earnings Miss: Aethlon Medical reported a Q3 GAAP EPS of -$2.45, missing estimates by $0.03, indicating ongoing challenges in profitability that could undermine investor confidence.
- Cash Reserves Pressure: As of December 31, 2025, Aethlon's cash balance stood at approximately $7.0 million, reflecting liquidity pressures that may limit future R&D and operational activities.
- Rising Operating Expenses: Consolidated operating expenses for Q3 2025 were approximately $2.06 million, up $250,000 or 13.6% from $1.81 million in the same period of 2024, suggesting challenges in cost control that could impact overall financial health.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance on Aethlon's future prospects, particularly as the company requires additional funding to support its R&D projects, potentially leading to stock price volatility.
See More
